Voya Investment Management LLC Sells 10,205 Shares of Henry Schein, Inc. $HSIC

Voya Investment Management LLC trimmed its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 27.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 26,716 shares of the company’s stock after selling 10,205 shares during the period. Voya Investment Management LLC’s holdings in Henry Schein were worth $1,773,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the 2nd quarter valued at $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Henry Schein in the 2nd quarter worth $43,000. Steph & Co. bought a new position in shares of Henry Schein during the 2nd quarter worth $44,000. Finally, CX Institutional increased its stake in shares of Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company’s stock valued at $48,000 after buying an additional 337 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Evercore ISI upped their price target on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Morgan Stanley increased their target price on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Finally, Barrington Research set a $79.00 price target on Henry Schein and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $76.92.

Henry Schein Trading Down 0.1%

NASDAQ:HSIC opened at $76.13 on Monday. The stock has a market capitalization of $8.96 billion, a price-to-earnings ratio of 24.09, a PEG ratio of 2.33 and a beta of 0.89. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The firm has a 50 day moving average of $71.79 and a 200 day moving average of $69.96.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.